Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
Palvella Therapeutics completed its pre-NDA meeting with the FDA for QTORIN™ rapamycin in microcystic lymphatic malformations. The company confirmed it remains on track to submit the New Drug Application in the second half of 2026, in line with prior guidance.
Key figures
- Drug Name
- QTORIN™ rapamycin
- Phase Of Trial
- Phase 3
- Target population us
- 30,000
- Nda submission window
- H2 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.